SRPT Stock Performance, Insider Transaction and News

SRPT - Sarepta Therapeutics, Inc.

Market Cap	9.80B	P/E	-	EPS this Y	126.70%	Ern Qtrly Grth	-
Income	47.3M	Forward P/E	45.73	EPS next Y	605.20%	50D Avg Chg	-11.00%
Sales	1.5B	PEG	0.84	EPS past 5Y	-	200D Avg Chg	-15.00%
Dividend	N/A	Price/Book	13.23	EPS next 5Y	96.00%	52W High Chg	-34.00%
Recommedations	1.70	Quick Ratio	2.69	Shares Outstanding	95.37M	52W Low Chg	9.00%
Insider Own	4.38%	ROA	0.73%	Shares Float	91M	Beta	0.81
Inst Own	93.75%	ROE	5.20%	Shares Shorted/Prior	6.15M/6.73M	Price	105.19
Gross Margin	37.13%	Profit Margin	3.14%	Avg. Volume	1,427,025	Target Price	188.73
Oper. Margin	-0.19%	Earnings Date	Oct 30	Volume	888,300	Change	-2.18%

Healthcare | Biotechnology | United States

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc. News

10/17/24	2 High-Flying Growth Stocks With Massive Upside Potential
10/16/24	Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
10/03/24	Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
09/30/24	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/30/24	Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?
09/26/24	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
09/23/24	Exploring TeraWulf And Two Other High Growth Tech Stocks
09/21/24	Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity
09/19/24	Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
09/16/24	Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
09/14/24	Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks
09/13/24	These 2 Biotech Stocks Are Set to Soar
09/08/24	Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar
09/06/24	Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
09/05/24	Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
09/03/24	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
08/30/24	DMD clinical studies evolve with emphasis on building designs around relevant endpoints
08/30/24	Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08/22/24	High Growth Tech Stocks To Watch In August 2024
08/20/24	Heard Writers Pick Their Favorite and Least-Favorite Stocks

SRPT Chatroom

biomaster22 Posted - 12 hours ago

$SRPT just can't seem to breakout

GetThePapersGetThePapers Posted - 15 hours ago

$SRPT been good lately

GetThePapersGetThePapers Posted - 15 hours ago

$SRPT like a virgin virgin virgin

Kanter1 Posted - 17 hours ago

$SRPT except for this trash biotech is screaming

GetThePapersGetThePapers Posted - 1 day ago

$SRPT this guy probably has never saw a woman naked in his life. He sits here all day cursing about his $1400 portfolio

Kanter1 Posted - 1 day ago

$SRPT fucking jokes on us

Kanter1 Posted - 1 day ago

$SRPT probably close down today You would think after 6 years theres a fiduciary responsibility to do what it tales to boost shareholder value But not these guy cause they dont give a fuck Ingram works 3 hours a day from his California home so he does not care Hes got it made

Kanter1 Posted - 1 day ago

$SRPT this idiot Kim on yahoo the dumbest fucking person in America Been pouding sarepta table for 7 years and has never been right

Kanter1 Posted - 1 day ago

$SRPT ingram and Barry got rich Ingram over 100 million So they could give a fuck about us

Kanter1 Posted - 1 day ago

$SRPT blow roche off and have bankers put company up for sale to highest bidder It wont be 15 or 16 billion tops but at this point who cares Investors been waiting over 5 years and have never been rewarded

Kanter1 Posted - 1 day ago

$SRPT ingram will blow away numbers and hype the pipeline on earnings day and the stock will hardly move Im willing to bet that without a bo sarepta will be in this area or lower a year from now Look what they achieved last 5 years and stock is flat to down And its him No large portfolio manager believes a word he says and retail investors moved on years ago and are not coming back A Doug Ingram resignation may help because his bullshit has done nothing for shareholders

Kanter1 Posted - 1 day ago

$SRPT we get excited if sarepta is up a buck or two Look at capr, wave today and bmea and all the others that 10 or 20 dollars and pop 3 oints in a day This is at 125 and when is last time this popped 3 points in a day Months ago

Kanter1 Posted - 1 day ago

$SRPT been hearing the lgmd story for a couple years Its sill a couple years away and just expands the dmd kids that can be dosed But its been a nothingburger so far

biomaster22 Posted - 1 day ago

$SRPT Kanter what about LGMD ?

Kanter1 Posted - 1 day ago

$SRPT sorry Jorge Noone buying sarepta be ause they were dumb enough to tie themselves to Roche making roche only possible buyer at any price And dont go by analyst numbers They have been wrong for 6 years And if sarepta gonna make a boatload of money for a year or two and than back to half those revs than noone will ever bid this above 150 The multiple will reduce for a couple years theres no other pipeline after 9001 approval So Ingram screwed investors Sarepta completely off the radar for investors hence the great biotech move while this remains pure crap There is nothing thats gonna boost this stock An upside earnings surprise will give you a 3 day pop

Broken_Bones_Jorge Posted - 1 day ago

$PFE $SRPT Unlikely that $PFE will go for a Multi-billion $ buyout in the midst of a shareholder proxy war... especially after the Seagen acquisition Listen... I am happy to be wrong as I am a $SRPT shareholder... but here are the facts -> $SRPT market cap is $12bn with a SP of $123. -> Brokers consensus has a SP of around $200-220 / share, without any control premium -> Control premium in biotech is 50%... so make it $300/share... -> That gives a takeover market value of $30bn -> Even if you assume that Roche acquires the EU business, that would leave the US and RoW business at around $20bn

Markus_Montag Posted - 2 days ago

$SRPT Well, it ain't my top performer, but I'm really thinkin' about pickin' up some more while it's just siting there trading sideways.

PhishTourFunds Posted - 2 days ago

$SRPT look at $123 SOLID support

biomaster22 Posted - 2 days ago

$SRPT biotechguy, please stop embarrassing yourself ! the last low of116 is it nothing but slow climb up until #'s release for 4th quarter in march of 2025 when we hit record revenues !

Biotechguy21 Posted - 2 days ago

$SRPT 105 soon?

Braveheart_13 Posted - 2 days ago

$ALT Might pull a $CAPR once the FDA meeting is complete in early Nov. Partnership announcement shortly afterward or further FDA feedback confirming trial design will send this skyward. Ridiculous that this is trading at 500M market cap when $VKTX is trading at 14B LOL. It's like CAPR and $SRPT... makes no sense. Truly feels like CAPR 2.0 let's get it

Kanter1 Posted - 2 days ago

$SRPT ingram worse ceo in America It was obvious Roche deal tied them up Now noone else would be interested And after 40 minutes 20 thousand shares at 124 as stocks break out massively Still fooling the stupid lazy analyst though After 6 years of Ingram bullshit they still take what he says as fact

Bates333 Posted - 2 days ago

$SRPT goodness gracious why

Thelonius_Stonk Posted - 2 days ago

$SRPT nevermind hehe

biomaster22 Posted - 3 days ago

$SRPT sorry okey dokey not this time !

Thelonius_Stonk Posted - 3 days ago

$SRPT this thing might finally be setting up again. good r/r vs the weekly 50ma imo

Okadarlan Posted - 3 days ago

$SRPT boring.. drop already

biomaster22 Posted - 3 days ago

$SRPT Doug you better be putting together a knockout quarter !

theflynews Posted - 3 days ago

Biotech Alert: Searches spiking for these stocks today - $SRPT - https://thefly.com/permalinks/entry.php/SRPTid3997854

PhishTourFunds Posted - 4 days ago

$SRPT $123 target acquired 💪

Analyst Ratings

Cantor Fitzgerald	Neutral	Sep 20, 24
RBC Capital	Outperform	Sep 19, 24
RBC Capital	Outperform	Sep 6, 24
RBC Capital	Outperform	Aug 15, 24
RBC Capital	Outperform	Aug 8, 24
Citigroup	Neutral	Aug 8, 24
Cantor Fitzgerald	Neutral	Aug 8, 24
Evercore ISI Group	Outperform	Aug 8, 24
Barclays	Overweight	Aug 8, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Barry Richard	Director Director	Nov 03	Buy	78.81	50,000	3,940,500	140,000	11/06/23
INGRAM DOUGLAS S	President & CEO President & CEO	Nov 03	Buy	79.97	25,225	2,017,243	390,307	11/06/23
BEHRENS M KATHLEEN	Director Director	Nov 03	Option	29.03	15,000	435,450	174,993	11/06/23
Chambers Michael Andrew	Director Director	Aug 14	Buy	109.54	9,979	1,093,100	246,996	08/15/23
Chambers Michael Andrew	Director Director	Aug 11	Buy	108.05	23,686	2,559,272	237,017	08/14/23
Chambers Michael Andrew	Director Director	Aug 10	Buy	105.61	34,867	3,682,304	213,331	08/11/23
Wigzell Hans Lennart Rudolf	Director Director	Aug 04	Sell	106.72	15,000	1,600,800	20,994	08/08/23
Wigzell Hans Lennart Rudolf	Director Director	Aug 04	Option	29.03	15,000	435,450	35,994	08/08/23
BEHRENS M KATHLEEN	Director Director	Dec 19	Option	34.92	20,000	698,400	158,470	12/21/22
Mayo Stephen	Director Director	Nov 17	Sell	109.92	858	94,311	6,387	11/21/22
Chambers Michael Andrew	Director Director	Sep 14	Buy	104.57	57,100	5,970,947	108,178	09/15/22
Chambers Michael Andrew	Director Director	Aug 19	Buy	108.5	46,170	5,009,445	51,078	08/22/22
BEHRENS M KATHLEEN	Director Director	Mar 10	Option	42.3	5,000	211,500	135,517	03/10/21
BEHRENS M KATHLEEN	Director Director	Mar 10	Sell	85.76	5,000	428,800	130,517	03/10/21
Wigzell Hans Lennart Rudolf	Director Director	Mar 10	Option	34.92	10,000	349,200	26,518	03/10/21
Wigzell Hans Lennart Rudolf	Director Director	Mar 10	Sell	83.51	10,000	835,100	16,518	03/10/21
Bratica Joseph	Principal Financial.. Principal Financial Officer	Dec 10	Option	29.6	1,125	33,300	9,265	12/10/20
Bratica Joseph	Principal Financial.. Principal Financial Officer	Dec 10	Sell	160	1,125	180,000	8,140	12/10/20